Tower Research Capital LLC TRC Purchases 28,345 Shares of Evolent Health, Inc. (NYSE:EVH)

Tower Research Capital LLC TRC increased its position in Evolent Health, Inc. (NYSE:EVH - Free Report) by 405.3% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 35,338 shares of the technology company's stock after acquiring an additional 28,345 shares during the quarter. Tower Research Capital LLC TRC's holdings in Evolent Health were worth $398,000 at the end of the most recent quarter.

Several other hedge funds also recently bought and sold shares of EVH. MetLife Investment Management LLC boosted its holdings in Evolent Health by 6.3% in the 4th quarter. MetLife Investment Management LLC now owns 70,915 shares of the technology company's stock valued at $798,000 after purchasing an additional 4,185 shares during the period. Mesirow Institutional Investment Management Inc. raised its position in shares of Evolent Health by 67.4% in the fourth quarter. Mesirow Institutional Investment Management Inc. now owns 701,927 shares of the technology company's stock worth $7,897,000 after buying an additional 282,509 shares in the last quarter. Dimensional Fund Advisors LP raised its position in shares of Evolent Health by 19.2% in the fourth quarter. Dimensional Fund Advisors LP now owns 2,897,443 shares of the technology company's stock worth $32,595,000 after buying an additional 466,225 shares in the last quarter. First Trust Advisors LP boosted its stake in Evolent Health by 401.8% during the fourth quarter. First Trust Advisors LP now owns 151,919 shares of the technology company's stock valued at $1,709,000 after buying an additional 121,645 shares during the period. Finally, Marshall Wace LLP grew its position in Evolent Health by 45.1% during the fourth quarter. Marshall Wace LLP now owns 94,320 shares of the technology company's stock worth $1,061,000 after buying an additional 29,328 shares in the last quarter.

Insider Buying and Selling at Evolent Health

In related news, President Daniel Joseph Mccarthy purchased 11,040 shares of the business's stock in a transaction that occurred on Thursday, March 6th. The shares were acquired at an average price of $9.01 per share, for a total transaction of $99,470.40. Following the completion of the acquisition, the president now directly owns 389,004 shares in the company, valued at approximately $3,504,926.04. The trade was a 2.92 % increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, Director Diane Holder acquired 2,735 shares of the firm's stock in a transaction on Thursday, March 6th. The stock was bought at an average price of $9.33 per share, with a total value of $25,517.55. Following the completion of the acquisition, the director now directly owns 70,584 shares in the company, valued at approximately $658,548.72. This represents a 4.03 % increase in their position. The disclosure for this purchase can be found here. Insiders acquired 74,000 shares of company stock valued at $666,315 in the last 90 days. Insiders own 1.60% of the company's stock.

Evolent Health Trading Down 1.2 %

Shares of NYSE EVH traded down $0.13 during mid-day trading on Tuesday, hitting $10.43. The stock had a trading volume of 161,001 shares, compared to its average volume of 2,362,588. The business has a 50 day moving average price of $9.50 and a two-hundred day moving average price of $11.83. Evolent Health, Inc. has a 1 year low of $8.35 and a 1 year high of $33.63. The company has a debt-to-equity ratio of 0.58, a quick ratio of 1.04 and a current ratio of 1.04. The firm has a market cap of $1.22 billion, a P/E ratio of -12.74 and a beta of 1.20.

Evolent Health (NYSE:EVH - Get Free Report) last released its quarterly earnings data on Thursday, February 20th. The technology company reported $0.03 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.38 by ($0.35). The firm had revenue of $646.54 million during the quarter, compared to analysts' expectations of $650.92 million. Evolent Health had a negative net margin of 2.41% and a positive return on equity of 5.73%. On average, equities analysts anticipate that Evolent Health, Inc. will post 0.08 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of analysts have recently issued reports on the company. Citigroup dropped their price target on Evolent Health from $21.00 to $18.00 and set a "buy" rating for the company in a research report on Friday, January 10th. Needham & Company LLC reiterated a "buy" rating and set a $15.00 target price on shares of Evolent Health in a research report on Friday, February 21st. Stephens cut their price target on shares of Evolent Health from $16.00 to $12.00 and set an "equal weight" rating for the company in a research note on Tuesday, January 21st. Royal Bank of Canada lowered their price objective on shares of Evolent Health from $20.00 to $17.00 and set an "outperform" rating on the stock in a research report on Tuesday, January 14th. Finally, JPMorgan Chase & Co. cut their target price on shares of Evolent Health from $13.00 to $12.00 and set an "overweight" rating for the company in a research report on Monday, March 10th. One analyst has rated the stock with a hold rating, twelve have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, Evolent Health has an average rating of "Buy" and an average target price of $17.71.

Evolent Health Company Profile

Evolent Health, Inc, through its subsidiary, Evolent Health LLC, offers specialty care management services in oncology, cardiology, and musculoskeletal markets in the United States. The company provides platform for health plan administration and value-based business infrastructure. It offers administrative services, such as health plan services, pharmacy benefits management, risk management, analytics and reporting, and leadership and management; and Identifi, a proprietary technology system that aggregates and analyzes data, manages care workflows, and engages patients.